Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.01
7% from low
Exchange
OTC Link
CS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2010 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72.7M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $32.9M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $39.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | 54.7% | — | — | — | — | — | — | — |
| R&D | $86.5K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $21.3M | −$21.8K | −$6.3K | −$30.4K | −$21.1K | −$18.8K | −$13.9K | −$29.0K |
| EBITDA | $17.6M | −$21.8K | −$6.3K | −$30.4K | −$21.1K | −$18.8K | $111.0K | −$29.0K |
| Net income | $14.4M | −$21.8K | −$6.3K | −$30.4K | −$21.1K | −$18.8K | $111.0K | −$29.0K |
| Net margin | 19.8% | — | — | — | — | — | — | — |
| EPS (diluted) | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Annual figures · source: Financial Modeling Prep
LOTUS PHARMS INC
No one on the platform currently holds LTUS.
No tracked institution reports a position in LTUS as of their last filing.
| Execution date | Ratio |
|---|---|
| 2010-12-31 | 1-for-2reverse |
No one on the platform has traded LTUS yet.
| $94641 |
| — |
| CDSGChina Dongsheng International, Inc. | $0.00 | +0.00% | $53628 | — |
| CHMJFWaverunner Capital Inc. | $0.02 | +0.00% | $114116 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.